Aktis Oncology (NASDAQ:AKTS) Sets New 1-Year Low – What’s Next?

Aktis Oncology (NASDAQ:AKTS)’s stock price hit a new 52-week low during mid-day trading on Friday . The company traded as low as $16.61 and last traded at $16.5650, with a volume of 49406 shares traded. The stock had previously closed at $17.62.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on AKTS shares. Bank of America began coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 price target for the company. Wall Street Zen raised Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. HC Wainwright started coverage on Aktis Oncology in a research report on Monday, March 9th. They set a “buy” rating and a $30.00 target price for the company. TD Cowen began coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Aktis Oncology currently has a consensus rating of “Buy” and a consensus price target of $31.25.

Aktis Oncology Trading Down 4.8%

The firm’s 50 day simple moving average is $19.37.

Insider Transactions at Aktis Oncology

In related news, major shareholder Ansbert Gadicke bought 1,112,777 shares of Aktis Oncology stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the acquisition, the insider directly owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. The trade was a 12.17% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ecor1 Capital, Llc purchased 2,222,222 shares of the stock in a transaction on Monday, January 12th. The shares were purchased at an average price of $18.00 per share, with a total value of $39,999,996.00. Following the acquisition, the director owned 4,348,658 shares in the company, valued at approximately $78,275,844. The trade was a 104.50% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 6,117,776 shares of company stock worth $110,119,968. 3.30% of the stock is currently owned by insiders.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.